Cargando…
Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis
PURPOSE: The glucagon-like peptide-1 receptor (GLP-1R) is an effective therapeutic target for type 2 diabetes mellitus (T2DM) and non-alcoholic steatohepatitis (NASH). Research has focused on small-molecule GLP-1R agonists because of their ease of use in oral formulations and improved patient compli...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184894/ https://www.ncbi.nlm.nih.gov/pubmed/37197367 http://dx.doi.org/10.2147/DDDT.S404055 |
_version_ | 1785042230845636608 |
---|---|
author | Xue, Huan Xing, Hao-Jie Wang, Bin Fu, Chao Zhang, Yu-Shan Qiao, Xi Guo, Chao Zhang, Xiao-Li Hu, Bin Zhao, Xin Deng, Li-Jiao Zhu, Xiao-Chan Zhang, Yi Liu, Yun-Feng |
author_facet | Xue, Huan Xing, Hao-Jie Wang, Bin Fu, Chao Zhang, Yu-Shan Qiao, Xi Guo, Chao Zhang, Xiao-Li Hu, Bin Zhao, Xin Deng, Li-Jiao Zhu, Xiao-Chan Zhang, Yi Liu, Yun-Feng |
author_sort | Xue, Huan |
collection | PubMed |
description | PURPOSE: The glucagon-like peptide-1 receptor (GLP-1R) is an effective therapeutic target for type 2 diabetes mellitus (T2DM) and non-alcoholic steatohepatitis (NASH). Research has focused on small-molecule GLP-1R agonists because of their ease of use in oral formulations and improved patient compliance. However, no small-molecule GLP-1R agonists are currently available in the market. We aimed to screen for a potential oral small-molecule GLP-1R agonist and evaluated its effect on blood glucose and NASH. METHODS: The Connectivity map database was used to screen for candidate small-molecule compounds. Molecular docking was performed using SYBYL software. Rat pancreatic islets were incubated in different concentrations glucose solutions, with cinchonine or Exendin (9–39) added to determine insulin secretion levels. C57BL/6 mice, GLP-1R(−/−) mice and hGLP-1R mice were used to conduct oral glucose tolerance test. In addition, we fed ob/ob mice with the GAN diet to induce the NASH model. Cinchonine (50 mg/kg or 100 mg/kg) was administered orally twice daily to the mice. Serum liver enzymes were measured using biochemical analysis. Liver tissues were examined using Hematoxylin-eosin staining, Oil Red O staining and Sirius Red staining. RESULTS: Based on the small intestinal transcriptome of geniposide, a recognized small-molecule GLP-1R agonist, we identified that cinchonine exerted GLP-1R agonist-like effects. Cinchonine had a good binding affinity for GLP-1R. Cinchonine promoted glucose-dependent insulin secretion, which could be attenuated significantly by Exendin (9–39), a specific GLP-1R antagonist. Moreover, cinchonine could reduce blood glucose in C57BL/6 and hGLP-1R mice, an effect that could be inhibited with GLP-1R knockout. In addition, cinchonine reduced body weight gain and food intake in ob/ob-GAN NASH mice dose-dependently. 100 mg/kg cinchonine significantly improved liver function by reducing the ALT, ALP and LDH levels. Importantly, 100 mg/kg cinchonine ameliorated hepatic steatosis and fibrosis in NASH mice. CONCLUSION: Cinchonine, a potential oral small-molecule GLP-1R agonist, could reduce blood glucose and ameliorate NASH, providing a strategy for developing small-molecule GLP-1R agonists. |
format | Online Article Text |
id | pubmed-10184894 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-101848942023-05-16 Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis Xue, Huan Xing, Hao-Jie Wang, Bin Fu, Chao Zhang, Yu-Shan Qiao, Xi Guo, Chao Zhang, Xiao-Li Hu, Bin Zhao, Xin Deng, Li-Jiao Zhu, Xiao-Chan Zhang, Yi Liu, Yun-Feng Drug Des Devel Ther Original Research PURPOSE: The glucagon-like peptide-1 receptor (GLP-1R) is an effective therapeutic target for type 2 diabetes mellitus (T2DM) and non-alcoholic steatohepatitis (NASH). Research has focused on small-molecule GLP-1R agonists because of their ease of use in oral formulations and improved patient compliance. However, no small-molecule GLP-1R agonists are currently available in the market. We aimed to screen for a potential oral small-molecule GLP-1R agonist and evaluated its effect on blood glucose and NASH. METHODS: The Connectivity map database was used to screen for candidate small-molecule compounds. Molecular docking was performed using SYBYL software. Rat pancreatic islets were incubated in different concentrations glucose solutions, with cinchonine or Exendin (9–39) added to determine insulin secretion levels. C57BL/6 mice, GLP-1R(−/−) mice and hGLP-1R mice were used to conduct oral glucose tolerance test. In addition, we fed ob/ob mice with the GAN diet to induce the NASH model. Cinchonine (50 mg/kg or 100 mg/kg) was administered orally twice daily to the mice. Serum liver enzymes were measured using biochemical analysis. Liver tissues were examined using Hematoxylin-eosin staining, Oil Red O staining and Sirius Red staining. RESULTS: Based on the small intestinal transcriptome of geniposide, a recognized small-molecule GLP-1R agonist, we identified that cinchonine exerted GLP-1R agonist-like effects. Cinchonine had a good binding affinity for GLP-1R. Cinchonine promoted glucose-dependent insulin secretion, which could be attenuated significantly by Exendin (9–39), a specific GLP-1R antagonist. Moreover, cinchonine could reduce blood glucose in C57BL/6 and hGLP-1R mice, an effect that could be inhibited with GLP-1R knockout. In addition, cinchonine reduced body weight gain and food intake in ob/ob-GAN NASH mice dose-dependently. 100 mg/kg cinchonine significantly improved liver function by reducing the ALT, ALP and LDH levels. Importantly, 100 mg/kg cinchonine ameliorated hepatic steatosis and fibrosis in NASH mice. CONCLUSION: Cinchonine, a potential oral small-molecule GLP-1R agonist, could reduce blood glucose and ameliorate NASH, providing a strategy for developing small-molecule GLP-1R agonists. Dove 2023-05-11 /pmc/articles/PMC10184894/ /pubmed/37197367 http://dx.doi.org/10.2147/DDDT.S404055 Text en © 2023 Xue et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Xue, Huan Xing, Hao-Jie Wang, Bin Fu, Chao Zhang, Yu-Shan Qiao, Xi Guo, Chao Zhang, Xiao-Li Hu, Bin Zhao, Xin Deng, Li-Jiao Zhu, Xiao-Chan Zhang, Yi Liu, Yun-Feng Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis |
title | Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis |
title_full | Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis |
title_fullStr | Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis |
title_full_unstemmed | Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis |
title_short | Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis |
title_sort | cinchonine, a potential oral small-molecule glucagon-like peptide-1 receptor agonist, lowers blood glucose and ameliorates non-alcoholic steatohepatitis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184894/ https://www.ncbi.nlm.nih.gov/pubmed/37197367 http://dx.doi.org/10.2147/DDDT.S404055 |
work_keys_str_mv | AT xuehuan cinchonineapotentialoralsmallmoleculeglucagonlikepeptide1receptoragonistlowersbloodglucoseandamelioratesnonalcoholicsteatohepatitis AT xinghaojie cinchonineapotentialoralsmallmoleculeglucagonlikepeptide1receptoragonistlowersbloodglucoseandamelioratesnonalcoholicsteatohepatitis AT wangbin cinchonineapotentialoralsmallmoleculeglucagonlikepeptide1receptoragonistlowersbloodglucoseandamelioratesnonalcoholicsteatohepatitis AT fuchao cinchonineapotentialoralsmallmoleculeglucagonlikepeptide1receptoragonistlowersbloodglucoseandamelioratesnonalcoholicsteatohepatitis AT zhangyushan cinchonineapotentialoralsmallmoleculeglucagonlikepeptide1receptoragonistlowersbloodglucoseandamelioratesnonalcoholicsteatohepatitis AT qiaoxi cinchonineapotentialoralsmallmoleculeglucagonlikepeptide1receptoragonistlowersbloodglucoseandamelioratesnonalcoholicsteatohepatitis AT guochao cinchonineapotentialoralsmallmoleculeglucagonlikepeptide1receptoragonistlowersbloodglucoseandamelioratesnonalcoholicsteatohepatitis AT zhangxiaoli cinchonineapotentialoralsmallmoleculeglucagonlikepeptide1receptoragonistlowersbloodglucoseandamelioratesnonalcoholicsteatohepatitis AT hubin cinchonineapotentialoralsmallmoleculeglucagonlikepeptide1receptoragonistlowersbloodglucoseandamelioratesnonalcoholicsteatohepatitis AT zhaoxin cinchonineapotentialoralsmallmoleculeglucagonlikepeptide1receptoragonistlowersbloodglucoseandamelioratesnonalcoholicsteatohepatitis AT denglijiao cinchonineapotentialoralsmallmoleculeglucagonlikepeptide1receptoragonistlowersbloodglucoseandamelioratesnonalcoholicsteatohepatitis AT zhuxiaochan cinchonineapotentialoralsmallmoleculeglucagonlikepeptide1receptoragonistlowersbloodglucoseandamelioratesnonalcoholicsteatohepatitis AT zhangyi cinchonineapotentialoralsmallmoleculeglucagonlikepeptide1receptoragonistlowersbloodglucoseandamelioratesnonalcoholicsteatohepatitis AT liuyunfeng cinchonineapotentialoralsmallmoleculeglucagonlikepeptide1receptoragonistlowersbloodglucoseandamelioratesnonalcoholicsteatohepatitis |